AR-12286 in Combination With Latanoprost

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Latanoprost 0.005%

q.d.

DRUG

AR-12286 Ophthalmic Solution 0.5%

DRUG

Timolol maleate ophthalmic solution 0.5%

Trial Locations (15)

12159

Glaucoma Consultants of the Capital Region, Slingerlands

14618

Rochester Ophthalmology Group, Rochester

19107

Wills Eye Hospital, Philadelphia

21209

Alan L Robin, M.D., Baltimore

28204

Thomas K. Mundorf, M.D., Charlotte

28210

Charlotte Eye Ear Nose and Throat, Charlotte

30076

Coastal Research Associates, LLC, Roswell

40217

Taustine Eye Center, Louisville

57701

Black Hills Regional Eye Institute, Rapid City

63090

Comprehensive Eye Care, St Louis

66204

Heart of America Eye Care, P.A., Shawnee Mission

74104

The Eye Institute, Tulsa

79902

Cataract & Glaucoma Center, El Paso

84117

Stacy R. Smith, M.D., Salt Lake City

06510

David Silverstone, M.D., New Haven

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT01302249 - AR-12286 in Combination With Latanoprost | Biotech Hunter | Biotech Hunter